New drugs targeting the immunoproteasome to treat Alzheimer's disease
Immunoproteasome inhibitors for the treatment of Alzheimers disease
This study is exploring a new type of medication that could help improve thinking and memory in people with Alzheimer's disease by working in a different way than usual treatments, and it aims to find options that are easier for the brain to use.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida International University NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project ID | NIH-11081729 on NIH RePORTER |
What this research studies
This research investigates a new class of drugs that target the immunoproteasome, which may help treat Alzheimer's disease by improving cognitive function without relying on the accumulation of amyloid-beta or tau proteins. The approach involves developing linear peptide epoxyketones that can potentially overcome challenges related to brain accessibility and metabolic stability. By focusing on a different mechanism than traditional Alzheimer's treatments, this research aims to identify effective therapies for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who are experiencing cognitive deficits.
Not a fit: Patients with Alzheimer's disease who do not have cognitive deficits or those with other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve cognitive function in Alzheimer's patients.
How similar studies have performed: While targeting the immunoproteasome is a novel approach, previous studies have shown promise in developing drugs that target proteasomes for various conditions.
Where this research is happening
Miami, United States
- Florida International University — Miami, United States (Active)
Researchers
- Principal investigator: Kim, Kyung Bo — Florida International University
- Study coordinator: Kim, Kyung Bo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.